LeadIQ logo
Learn more at LeadIQ.com

Insights

First-in-Class Cancer Treatments BerGenBio focuses on developing selective AXL kinase inhibitors for aggressive cancers, presenting a unique and promising solution in the oncology market.

Global Leader in AXL Kinase Understanding The company's expertise in AXL kinase's role in cancer progression positions them as a thought leader in the field, opening doors for collaborations and partnerships with healthcare institutions and research organizations.

Innovative Technology Stack The use of advanced technologies such as Cookiebot, PHP, and Nginx showcases BerGenBio's commitment to innovation, appealing to tech-savvy healthcare clients seeking cutting-edge solutions.

Solid Financial Foundation With a revenue range of $0-10M and $23M in funding, BerGenBio demonstrates financial stability and growth potential, suggesting a reliable partner for investors and customers looking for long-term relationships.

Competitive Landscape Analysis By comparing employee size and revenue with similar companies like Iterum Therapeutics and Nabriva Therapeutics, BerGenBio gains insights into market positioning and opportunities for market expansion and competitive differentiation.

Similar companies to BerGenBio ASA

BerGenBio ASA Tech Stack

BerGenBio ASA uses 8 technology products and services including Cookiebot, yepnope.js, OWL Carousel, and more. Explore BerGenBio ASA's tech stack below.

  • Cookiebot
    Cookie Compliance
  • yepnope.js
    Javascript Frameworks
  • OWL Carousel
    Javascript Libraries
  • Lodash
    Javascript Libraries
  • Priority Hints
    Performance
  • PHP
    Programming Languages
  • Yoast SEO
    Search Engines
  • Nginx
    Web Servers

Media & News

BerGenBio ASA's Email Address Formats

BerGenBio ASA uses at least 1 format(s):
BerGenBio ASA Email FormatsExamplePercentage
First.Last@bergenbio.comJohn.Doe@bergenbio.com
49%
Last@bergenbio.comDoe@bergenbio.com
1%
First_Last@bergenbio.comJohn_Doe@bergenbio.com
1%
First.Last@bergenbio.comJohn.Doe@bergenbio.com
49%

Frequently Asked Questions

Where is BerGenBio ASA's headquarters located?

Minus sign iconPlus sign icon
BerGenBio ASA's main headquarters is located at Jonas Lies vei 91 Bergen, Norway, NO. The company has employees across 3 continents, including EuropeNorth AmericaAsia.

What is BerGenBio ASA's phone number?

Minus sign iconPlus sign icon
You can contact BerGenBio ASA's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is BerGenBio ASA's official website and social media links?

Minus sign iconPlus sign icon
BerGenBio ASA's official website is bergenbio.com and has social profiles on LinkedIn.

How much revenue does BerGenBio ASA generate?

Minus sign iconPlus sign icon
As of July 2024, BerGenBio ASA's annual revenue reached $3.8M.

What is BerGenBio ASA's SIC code NAICS code?

Minus sign iconPlus sign icon
BerGenBio ASA's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does BerGenBio ASA have currently?

Minus sign iconPlus sign icon
As of July 2024, BerGenBio ASA has approximately 24 employees across 3 continents, including EuropeNorth AmericaAsia. Key team members include Chief Executive Officer: M. O.Chief People Officer: D. M.Chief Business Officer: G. M.. Explore BerGenBio ASA's employee directory with LeadIQ.

What industry does BerGenBio ASA belong to?

Minus sign iconPlus sign icon
BerGenBio ASA operates in the Biotechnology Research industry.

What technology does BerGenBio ASA use?

Minus sign iconPlus sign icon
BerGenBio ASA's tech stack includes Cookiebotyepnope.jsOWL CarouselLodashPriority HintsPHPYoast SEONginx.

What is BerGenBio ASA's email format?

Minus sign iconPlus sign icon
BerGenBio ASA's email format typically follows the pattern of . Find more BerGenBio ASA email formats with LeadIQ.

How much funding has BerGenBio ASA raised to date?

Minus sign iconPlus sign icon
As of July 2024, BerGenBio ASA has raised $23M in funding. The last funding round occurred on Nov 30, 2023 for $23M.

When was BerGenBio ASA founded?

Minus sign iconPlus sign icon
BerGenBio ASA was founded in 2008.
BerGenBio ASA

BerGenBio ASA

Biotechnology ResearchBergen, Norway, Norway11-50 Employees

BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers. 

The Company is a world leader in understanding the central role of AXL kinase in promoting cancer spread, immune evasion and drug resistance – the cause of approximately 90 percent of cancer deaths. 

Inhibition of AXL kinase activity represents a novel approach to addressing a key mechanism in the evolution of cancer cell malignancy and aggressiveness, offering an opportunity to create important new therapeutic options for cancer patients.

Section iconCompany Overview

Headquarters
Jonas Lies vei 91 Bergen, Norway, NO
Phone number
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2008
Employees
11-50

Section iconFunding & Financials

  • $23M

    BerGenBio ASA has raised a total of $23M of funding over 10 rounds. Their latest funding round was raised on Nov 30, 2023 in the amount of $23M.

  • $10M

    BerGenBio ASA's revenue is in the range of $10M

Section iconFunding & Financials

  • $23M

    BerGenBio ASA has raised a total of $23M of funding over 10 rounds. Their latest funding round was raised on Nov 30, 2023 in the amount of $23M.

  • $10M

    BerGenBio ASA's revenue is in the range of $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.